Evaluating the Efficacy, Safety and Long Term Functional Outcomes of Percutaneous Mechanical Aspiration Thrombectomy for Treatment of Acute Pulmonary Embolism Using the AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System
← catalyst calendarNCT06697314 · readout ≤ 681 d
Sponsored by Angiodynamics, Inc. (industry) · ANGO — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
256estimated
Sites
1
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-15 | actual | When the study began enrolling |
| Primary completion | Jun 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Acute Pulmonary Embolism (PE)
- Pulmonary Embolism
Intervention
- Device: AlphaVac Multipurpose Mechanical Aspiration (MMA) F1885 System — also filed as thrombectomy, mechanial aspiration
Primary outcomes
what the primary-completion date above is the date OFReduction in RV/LV ratio
measured 48 hours
Incidence of Adverse Events [Safety and Tolerability]
measured 12 months
Permalink · ANGO's whole pipeline · Catalyst calendar · Every registered study · What changed